
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
This medicinal product may not have a marketing authorization in your country, may have been allocated via COVAX or may have an authorization for Emergency Use only as granted by the the relevant national health regulatory authority. It is used for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals within the authorized age range. Please refer to the enclosed COVID-19 mRNA Vaccine (BNT162b2) product information (via the link or enclosed) for important treatment considerations regarding the vaccine. This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.
COVID-19 mRNA vaccine (BNT162)
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.